AbbVieKPI data tables
AbbVie operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | United States | International |
|---|---|---|
| Other Aesthetics | 258 | 51 |
| Juvederm | 103 | 142 |
| Botox Cosmetic | 400 | 328 |
Source: AbbVie Q2 2026 Form 8-K Exhibit 99.1 Net Revenues table, three months ended 30 June 2026: Botox Cosmetic, Juvederm, Other Aesthetics United States and International columns. https://news.abbvie.com/2026-07-31-AbbVie-Reports-Second-Quarter-2026-Financial-Results. SEC: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm.
| Period | United States | International |
|---|---|---|
| Q3 2026 | 388 | 281 |
| Q2 2026 | 400 | 328 |
| Q1 2026 | 371 | 297 |
Source: AbbVie Q1 2026, Q2 2026 and Q3 2026 Form 8-K Exhibit 99.1 Net Revenues tables, Botox Cosmetic United States and International. Q2: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm. Q3: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/abbv-20260930xexhibit991.htm.
| Period | United States | International |
|---|---|---|
| Humira | 425 | 331 |
| Rinvoq | 1,765 | 760 |
| Skyrizi | 4,767 | 738 |
Source: AbbVie Form 8-K Exhibit 99.1 second-quarter 2026 earnings release, Net Revenues table (Immunology franchise, United States and International columns), three months ended June 30, 2026. Year-over-year percentage changes cited in the description are from the same table.
| Period | United States | International |
|---|---|---|
| Q2 2026 Neuroscience | 2,771 | 457 |
Source: AbbVie Q2 2026 Form 8-K Exhibit 99.1: Neuroscience portfolio United States $2,771 million, International $457 million; Vraylar $1,071 million. https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm.